Print

Cancer Research Consortium of West Michigan

Breast Clinical Trials

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.

Provided drugs are underlined

For more information, call the CRCWM Main office at 616.391.1230 or 800.336.5079

Narrow List by Age:

Breast

Cancer Type: ER(+) NeoAdjuvant
Research Base: Alliance
Protocol: Alliance A011106 Neoadjuvant

A011106: ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: a phase III study

Cancer Type: METASTATIC BREAST CANCER
Research Base: SWOG
Protocol: SWOG S1703

RANDOMIZED NON-INFERIORITY TRIAL COMPARING OVERALL SURVIVAL OF PATIENTS MONITORED WITH SERUM TUMOR MARKER DIRECTED DISEASE MONITORING (STMDDM) VERSUS USUAL CARE IN PATIENTS WITH METASTATIC HORMONE RECEPTOR POSITIVE BREAST CANCER

Cancer Type: Low Risk DCIS
Research Base: AFT
Protocol: AFT - 25 COMET

COMPARISON OF OPERATIVE TO MONITORING AND ENDOCRINE THERAPY (COMET) TRIAL FOR LOW RISK DCIS: A PHASE III PROSPECTIVE RANDOMIZED TRIAL

Cancer Type: LOW RISK NODE POSITIVE BREAST CANCER
Research Base: NRG
Protocol: CCTG MA.39 Adjuvant

TAILOR RT: A RANDOMIZED TRIAL OF REGIONAL RADIOTHERAPY IN BIOMARKER LOW RISK NODE POSITIVE BREAST CANCER

Cancer Type: High-Risk, ER/PR+ and HER2/neu -
Research Base: SWOG
Protocol: SWOG S1207 Adjuvant

SWOG S1207: Phase III randomized trial. Endocrine Therapy + Everolimus/Placebo. High-risk hormone receptor positive and HER2/NEU negative breast cancer. Staging I-III.

Cancer Type: Triple-Negative Invasive Breast Cancer
Research Base: NRG
Protocol: NRG BR003 Adjuvant

NRG BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

Cancer Type: Triple-Negative Basal-Like Breast Cancer
Research Base: ECOG-ACRIN
Protocol: EA1131 Adjuvant

ECOG EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Cancer Type: Triple(-); ypT1or ypN(+)
Research Base: SWOG
Protocol: SWOG S1418 Adjuvant

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy

Cancer Type: ER/PgR Any; Her2 Negative; Post Adjuvant
Research Base: NRG
Protocol: NSABP B-55 Adjuvant

NSABP B55: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Center Phase III Study. Olaparib vs Placebo. Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy. 

Cancer Type: RT for (+)Node?Neo Chemo f/b surg?(-)Node
Research Base: NRG
Protocol: NSABP B-51 Adjuvant

NSABP B-51: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy. 

Cancer Type: Breast Cancer
Research Base: Alliance
Protocol: Alliance A011202 Adjuvant

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Cancer Type: Breast Cancer
Research Base: Alliance
Protocol: Alliance A221505 Adjuvant

PHASE III RANDOMIZED TRIAL OF HYPOFRACTIONATED POST MASTECTOMY RADIATION WITH BREAST RECONSTRUCTION

Cancer Type: Metastatic Breast Cancer
Research Base: AFT
Protocol: AFT - 38 Patina Metastatic

AFT-38 PATINA:A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Cancer Type: Mets; Triple Negative
Research Base: SWOG
Protocol: SWOG S1416 Metastatic

Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer

Cancer Type: HER2 Positive Breast Cancer w/Brain Mets
Research Base: NRG
Protocol: RTOG 1119 Metastatic

RTOG 1119: Phase II Randomized Study. WBRT +/- Lapatinib in patients with brain metastasis from HER2-Positive breast cancer. Stage IV.

Cancer Type: Metastatic Breast Cancer (MBC)
Research Base: Sarah Cannon
Protocol: SCRI BRE 203 Metastatic

SCRI BRE 203: A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR).  

Cancer Type: Breast Cancer
Research Base: Alliance
Protocol: Alliance A011104 CC Breast MRI

Alliance A011104: Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer

Cancer Type: Breast cancer
Research Base: Alliance
Protocol: Alliance A011401 CC Weight loss

Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Cancer Type: Node Positive Her2 Negative Breast Cancer
Research Base: Alliance
Protocol: Alliance A011502 CC ASA

A RANDOMIZED PHASE III DOUBLE BLINDED PLACEBO CONTROLLED TRIAL OF ASPIRIN AS ADJUVANT THERAPY FOR NODE POSTIVE HER2 NEGATIVE BREAST CANCER: THE ABC TRIAL

Cancer Type: BREAST OR GYNECOLOGIC CANCER
Research Base: NRG
Protocol: NRG CC004 CC-Sexual Desire

PHASE II DOUBLE BLIND DOSE FINDING TRIAL OF BUPROPION VERSUS PLACEBO FOR SEXUAL DESIRE IN WOMEN WITH BREAST OR GYNECOLOGIC CANCER

Cancer Type: METASTATIC HER-2+ BREAST CANCER
Research Base: SWOG
Protocol: SWOG S1501 CC cardiac tox

S1501:  PROSPECTIVE EVALUATION OF CARVEDILOL IN PREVENTION OF CARDIAC TOXICITY IN PATIENTS WITH METASTATIC HER-2+ BREAST CANCER, PHASE III

Cancer Type: Cancer Control
Research Base: URCC
Protocol: URCC 16070 CC nausea

TREATMENT OF REFRACTORY NAUSEA

Cancer Type: Breast Cancer
Research Base: Wake Forest
Protocol: WF 97116 CC/cog impair

WF 97116:  A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors with Cognitive Impairment

Cancer Type: Breast Adjuvant
Research Base: testy
Protocol: Testing 123

Testing 123